Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition.

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-03-30 eCollection Date: 2023-01-01 DOI:10.1080/2162402X.2023.2197360

Laura Codarri Deak, Masao Hashimoto, Pablo Umaña, Christian Klein

引用次数: 0

Abstract

The immunocytokine PD1-IL2v was designed to overcome liabilities and improve efficacy of IL-2 therapies. PD1-IL2v preferentially targets PD-1⁺ T-cells and acts on antigen-specific stem-like PD-1⁺ TCF-1⁺ CD8⁺ T-cells expanding and differentiating them towards better effectors resulting in superior efficacy in LCMV chronic infection and tumor models compared to checkpoint inhibition.

Abstract Image

查看原文本刊更多论文

超越检查点抑制：PD-1顺式靶向il - 2r βγ偏倚的白介素-2变体作为建立检查点抑制的新方法。

免疫细胞因子PD1-IL2v被设计用于克服缺陷并提高IL-2治疗的疗效。PD1-IL2v优先靶向PD-1+ t细胞，并作用于抗原特异性干细胞样PD-1+ TCF-1+ CD8+ t细胞，使其扩增并分化为更好的效应器，与检查点抑制相比，在LCMV慢性感染和肿瘤模型中具有更好的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.